BioTuesdays

Category - Developments

Aurinia

Aurinia to begin Phase 3 voclosporin trial in Q2

After an end-of-Phase 2 meeting with the FDA, Aurinia Pharmaceuticals (NASDAQ:AUPH) plans to begin a single Phase 3 clinical trial for voclosporin in the treatment of lupus nephritis (LN). Aurinia believes the Phase 3...

Turnstone Biologics

Turnstone Biologics in $41.4-million financing

Closely-held Turnstone Biologics has completed a $41.4-million series B financing led by new investor, OrbiMed, with participation from another new investor, F-Prime Capital Partners, and existing investors, FACIT and...

Titan Pharmaceuticals

Titan’s Probuphine featured at ISAM meeting

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant was featured in three presentations at the International Society of Addiction Medicine (ISAM) annual meeting in Montreal last week. Probuphine, a subdermal implant...

Mati Therapeutics

New U.S. patent expands Mati’s IP portfolio

Closely-held Mati Therapeutics has been granted a U.S. patent covering a method of providing a sustained drug release to an eye using a proprietary punctal plug design placed in the punctum (tear duct) over a treatment...

Dipexium Pharmaceuticals

Dipexium updates availability of Phase 3 data

Dipexium Pharmaceuticals (NASDAQ:DPRX) updated the status of results from two pivotal Phase 3 clinical trials – OneStep-1 and OneStep-2- of its topical antimicrobial peptide, Locilex, for the treatment of diabetic...

Avivagen

Avivagen in OxC-beta pact with UNAHCO

Avivagen (TSX-V:VIV) has agreed to supply OxC-beta Livestock to UNAHCO for sales and distribution in the Republic of the Philippines. OxC-beta has been shown to be effective and economic in replacing the antibiotics...

Subscribe

Sign up to our weekly BioTuesdays newsletter.